A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Kuei-Ting ChenRussell W MadisonJay MooreDexter JinZoe FleischmannJustin NewbergAlexa SchrockNeeru BhardwajKatherine T LofgrenJie HeGarrett FramptonPriti HegdeDavid FabrizioMichael J PishvaianEricka EbotAatur SinghiEthan SokolPublished in: The oncologist (2023)
A scar-based HRD biomarker was identified in a significant fraction of PC patients and is predictive of FOLFIRINOX benefit. Incorporating a biomarker like HRDsig could identify the right patients for platinum chemotherapy and potentially reduce FOLFIRINOX use by over 40%, minimizing toxicities with similar survival outcomes. Confirmatory studies should be performed.